Navigation Links
Cyberonics Announces Investment In cerbomed GmbH
Date:9/20/2012

HOUSTON, Sept. 20, 2012 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ: CYBX), a global leader in medical devices for the treatment and management of epilepsy, today announced an initial investment of € 2 million in cerbomed GmbH ("cerbomed").  Based in Erlangen, Germany, cerbomed is a privately-held company developing a non-invasive neurostimulation device for the treatment of epilepsy.  The NEMOS® t-VNS device received CE Mark approval for the treatment of epilepsy and depression in 2010 and for pain in 2012 and is now commercially available in Germany and Austria.

The investment in cerbomed can total up to € 5.5 million, subject to the achievement of certain clinical milestones.  Cyberonics is a minority shareholder with certain rights, including representation on cerbomed's advisory board and an exclusive option for worldwide sales and distribution of the NEMOS system for the treatment of epilepsy.  The initial investment will be used to fund cerbomed's current clinical trial in epilepsy in Germany.  Subject to certain conditions, Cyberonics has the option to conduct a trial in the U.S. for the purpose of seeking FDA approval. 

"As a company focused on device solutions for epilepsy, an investment in cerbomed's technology is aligned with our strategic priorities and core expertise," said Dan Moore, Cyberonics' President and Chief Executive Officer.  "We are excited about the opportunity to invest in a technology that may provide more patients with epilepsy another device-based therapeutic option and opportunity for improved quality of life."

Andreas Hartlep, cerbomed's Chief Executive Officer, added, "We are delighted to welcome Cyberonics, the world market leader in vagus nerve stimulation, as our strategic global partner for the epilepsy indication.  We look forward to
'/>"/>

SOURCE Cyberonics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cyberonics To Participate In Upcoming September Investor Conferences
2. Cyberonics To Present At Morgan Stanley 2012 Global Healthcare Conference
3. Cyberonics To Report Fiscal Year 2013 First Quarter Results And Host Conference Call On August 28, 2012
4. ULURU Inc. Announces First Order Of Altrazeal For European Launch
5. United Therapeutics Announces Collaboration With Ascendis Pharma To Develop Self-Injectable Treprostinil For Pulmonary Arterial Hypertension
6. FDAnews announces Third Annual Pharmaceutical Labeling Summit
7. CVS Caremark Corporation Announces New Share Repurchase Authorization for up to $6 Billion of Common Stock
8. PRN Physician Recommended Nutriceuticals announces partnership with Dr. Eric Donnenfeld and expansion in the New York City metropolitan area
9. InnoPharma, Inc., Announces U.S. FDA Approval of Acetylcysteine Solution, USP, 20% for Inhalation or Oral Administration
10. Specialty Pharmacy Certification Board Announces Inaugural Board of Directors
11. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... COLORADO SPRINGS, Colo. , July 29, 2014 /PRNewswire-USNewswire/ ... remote-controlled catheter (MARC) which could allow physicians to see ... stroke may hold promise, according to study authors who ... Surgery (SNIS) 11 th Annual Meeting in ... findings stand to advance the field of neurointervention, a ...
(Date:7/29/2014)... NASHVILLE, Tenn. and NEW YORK ... and member of the executive management team of Caremark ... of PBM365 Media ( www.pbm365.com ).  PBM365 is the ... and unbiased reporting, insight, analysis and opinion on ... PBM365 will provide insightful and timely coverage of, ...
(Date:7/29/2014)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) launched its presence ... Clinical Lab Expo today by unveiling two booths (#1209 ... partnering with customers to redefine the value of the ... that they,re looking for a partner to help them ... offices," said Jack Phillips , president and CEO ...
Breaking Medicine Technology:New Technology May Improve Visualization Of The Brain During Stroke Treatment 2New Technology May Improve Visualization Of The Brain During Stroke Treatment 3Drew Crawford Announces Launch of PBM365 Media 2Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 2Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 3Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 4
... Inc . announced today that David A. Weber, Ph.D. , ... Board of Directors. Jay Lichter, Ph.D., managing director of Avalon Ventures, ... actively support the company as a member of the Board of ... to the Otonomy team, as his extensive experience in the development ...
... 2010 Amicus Therapeutics (Nasdaq: FOLD ), ... diseases, today announced that it has been awarded a ... Parkinson,s Research (MJFF) for the development of a novel, ...  The $500,000 award will be distributed over a period ...
Cached Medicine Technology:Otonomy Appoints David A. Weber, Ph.D., Chief Executive Officer 2Otonomy Appoints David A. Weber, Ph.D., Chief Executive Officer 3Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 2Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 3Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 4Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 5
(Date:7/29/2014)... HealthDay Reporter TUESDAY, July 29, 2014 ... a single dose of the hormone oxytocin quickly improved their ... Known as the "love hormone," oxytocin has been shown ... between mothers and their children. In this study, it ... brain that has long been associated with the processing of ...
(Date:7/29/2014)... 29, 2014 During his 37 years in ... & Associates, has had a steady stream of college students ... students have now gone on to dental school and some ... the shadowing program helps college students find success. , For ... given them the chance to see a realistic view of ...
(Date:7/29/2014)... that helps headache sufferers to record the severity and ... of a Griffith research study. , A new approach ... at coping with their triggers and is being led ... Basis of Health program. , He has developed an ... triggers of their headaches called Learning to Cope with ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Child abuse law ... law students this week. The scholarship will help future lawyers ... and their families. , Steinger, Iscoe and Greene lawyers work ... want tomorrow’s attorneys to do the same. More than 6 ... according to the nonprofit Childhelp (retrieved 7/22/2014). , ...
(Date:7/29/2014)... NJ (PRWEB) July 29, 2014 Helping ... is an immensely complex challenge that requires deep knowledge ... knowledge to improve therapeutic options and outcomes has been ... professor of biomedical engineering, since he joined the NJIT ... whose significance is underscored by substantial funding from sources ...
Breaking Medicine News(10 mins):Health News:'Love Hormone' Oxytocin May Help Some With Autism 2Health News:'Love Hormone' Oxytocin May Help Some With Autism 3Health News:Arthur Bruce Dental Helps College Students 2Health News:Steinger, Iscoe & Greene Offers Child Advocate Scholarship 2Health News:Continuing the Quest for Better Stroke Therapies 2Health News:Continuing the Quest for Better Stroke Therapies 3Health News:Continuing the Quest for Better Stroke Therapies 4
... VNUS(R) Medical,Technologies, Inc. (Nasdaq: VNUS ), a leading ... venous reflux disease, today,announced the appointment of Peter Osborne ... Administration., Mr. Osborne joins VNUS with over 25 ... Osborne had served as the Company,s,Interim CFO since October ...
... 3 times weekly may increase risk, study suggests , , ... a Mediterranean diet rich in fish, fresh fruits and vegetables, ... their children against asthma and allergies, new research suggests. , ... included 468 mother and child pairs that were followed from ...
... Matters of the mind can affect matters of the heart. ... researchers has found that major anxiety and/or depression, can double ... This is one of the first studies to focus on ... were hospitalized for events such as a heart attack. , ...
... be saved , , FRIDAY, Jan. 18 (HealthDay News) -- If ... die from sudden cardiac arrest could be dramatically reduced. , ... calling for renewed efforts to teach CPR and to find ... the lifesaving technique. , "There is a tremendous opportunity for ...
... Jan. 18 LifeSync Corporation is,pleased to announce ... of Operations. Ms. McLane comes to LifeSync Corporation ... Johnson Company, where she,most recently held the position ... joining Cordis, Ms. McLane spent over 13,years at ...
... brain tumors, dual implantation of radioactive seeds and ... a study led by specialists at the Neuroscience ... University Hospital. , The study, published in the ... that patients treated with simultaneous implantation of radioactive ...
Cached Medicine News:Health News:VNUS Medical Technologies Appoints Peter Osborne as Chief Financial Officer 2Health News:Mediterranean Diet for Mom Fends Off Asthma, Allergies in Kids 2Health News:Depression and anxiety can double chances of heart ailments 2Health News:Heart Association Renews Call for CPR Training 2Health News:Heart Association Renews Call for CPR Training 3Health News:LifeSync Corporation Appoints Nancy McLane as Senior Vice President Operations 2Health News:Combined radiation seed, chemotherapy wafer implants show promise in treating cancerous brain tumors 2
Colloidal Gold Conjugated, Protein A - 12 OD...
Polyester ribbons (3) impregnated with different OD values of conjugated Protein G...
Colloidal Gold Conjugated, Protein G - 12 OD...
Colloidal Gold Sol, 40 nm - 50 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
Medicine Products: